Download PDFPDF

402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address